(Q87942292)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29500134%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

title

Cost and cost-effectiveness studies in urologic oncology using large administrative databases (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29500134%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

author name string

Ye Wang

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29500134%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Matthew Mossanen

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29500134%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Steven L Chang

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29500134%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

publication date

2 March 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29500134%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29500134%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

volume

36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29500134%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29500134%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

page(s)

213-219

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29500134%20AND%20SRC:MED&resulttype=core&format=json

Projections of the cost of cancer care in the United States: 2010-2020.

19 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

The burden of bladder cancer care: direct and indirect costs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

The health economics of bladder cancer: an updated review of the published literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

The economic burden of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

A review of economic evaluations of diagnostic strategies using imaging in men at risk of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Cost consideration in utilization of multiparametric magnetic resonance imaging in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Cost-effectiveness of multiparametric magnetic resonance imaging and targeted biopsy in diagnosing prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Cost-effectiveness of magnetic resonance (MR) imaging and MR-guided targeted biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer: a modelling study from a health care perspective.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Cost-Effectiveness Comparison of Imaging-Guided Prostate Biopsy Techniques: Systematic Transrectal Ultrasound, Direct In-Bore MRI, and Image Fusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Cost of New Technologies in Prostate Cancer Treatment: Systematic Review of Costs and Cost Effectiveness of Robotic-assisted Laparoscopic Prostatectomy, Intensity-modulated Radiotherapy, and Proton Beam Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Cost-effectiveness of open versus laparoscopic versus robotic-assisted laparoscopic cystectomy and urinary diversion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Testicular self-examination and testicular cancer: a cost-utility analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Cost-effectiveness analysis of nephron sparing options for the management of small renal masses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Decision analytic cost-effectiveness model to compare prostate cryotherapy to androgen deprivation therapy for treatment of radiation recurrent prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Cost-effectiveness of Management Options for Small Renal Mass: A Systematic Review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Cost-effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

The Cost-Effectiveness of Immediate Treatment, Percutaneous Biopsy and Active Surveillance for the Diagnosis of the Small Solid Renal Mass: Evidence From a Markov Model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Renal mass biopsy to guide treatment decisions for small incidental renal tumors: a cost-effectiveness analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Radiofrequency ablation versus nephron-sparing surgery for small unilateral renal cell carcinoma: cost-effectiveness analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

A cost-effectiveness analysis of management of low-risk non-muscle-invasive bladder cancer using office-based fulguration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Cost-effectiveness of neoadjuvant chemotherapy before radical cystectomy for muscle-invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Contemporary cost-effectiveness analysis comparing sequential bacillus Calmette-Guerin and electromotive mitomycin versus bacillus Calmette-Guerin alone for patients with high-risk non-muscle-invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Measurement of health state utilities for economic appraisal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Assessment of health-related quality of life after radiofrequency ablation or laparoscopic surgery for small renal cell carcinoma: a prospective study with medical outcomes Study 36-Item Health Survey (SF-36).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Quality of life and perioperative outcomes after retroperitoneoscopic radical nephrectomy (RN), open RN and nephron-sparing surgery in patients with renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Quality of life after surgery for localized renal cell carcinoma: comparison between radical nephrectomy and nephron-sparing surgery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Patient-reported outcomes: A new era in clinical research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Markov models in medical decision making: a practical guide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

An introduction to Markov modelling for economic evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Handling uncertainty in cost-effectiveness models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Use of pharmacoeconomics in prescribing research. Part 5: modelling--beyond clinical trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Robot-assisted Versus Open Radical Prostatectomy: A Contemporary Analysis of an All-payer Discharge Database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2018.01.015

10.1016/J.UROLONC.2018.01.015

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29500134%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

1 reference